Engineering Lactobacillus casei Services for Live Biotherapeutics Drug Discovery
Backgrounds Services Advantages Published Data Resources
Delivering functional proteins with genetically engineered lactic acid bacteria (LAB) is a promising approach, especially in oral drug delivery development, where it can effectively protect proteins from digestion by proteases and induce effective function. The LAB expression system has been widely used in the development of oral vaccines, and its effects have been proven in vitro and in vivo. Creative Biolabs is an innovative, experienced provider of custom live biotherapeutic product (LBP) services, we understand that each customer's requirements are different, and a variety of engineering Lactobacillus casei (L. casei) services are available according to the client's research objectives.
Background
Probiotics have the advantages of long survival time in vivo, low toxicity, convenient culture, etc., and can be used as vaccine carriers to deliver different antigens (foreign immunogens). Because they are generally considered safe, certain strains of L. casei are considered potentially therapeutic and ideal candidates for delivering therapeutic and preventative moleculesin vivo for human and animal health to modulate T-helper cell responses and stimulate the secretion of specific IgAs, thereby enabling mucosal immunity. Currently, L. casei gene-editing techniques rely on plasmid-based homologous recombination, which takes at least 24 days to produce a gene knockout. The gene editing system reduces the cycle time to nine days. In addition, pLCNICK has proven to be an effective, fast, and accurate genome editing tool for L. casei.
Fig.1 Overview of Cas9D10A nickase-assisted recombineering in L. casei.1
Engineering Lactobacillus casei Services
Services
-
Gene knock-out
-
Gene knock-in/Gene insertion
Deliverables
Engineered strain in glycerol stock
Quality Control
-
Sequencing Validation
-
Western Blot Validation (Optional)
-
PAGE
-
or cell-based assay of your interest.
Delivery Time
Starting from 4-6 weeks.
Materials from Clients
-
Overall construction scheme.
-
Host strain
-
Target gene name
-
Target gene sequence, if the whole genome sequence is unavailable
How Lactobacillus casei Strain Construction Service Can Assist Your Project
-
Construct the target strains according to the needs of clients or referring to the published scheme.
-
Optimize the program to improve the success rate.
-
Delivery of the constructed target strains (knockout or integrated).
Advantages
-
Genetically engineered L. casei with vaccine and pharmaceutical purposes can be directly applied orally.
-
The L. casei vaccine strain is a safe probiotic microorganism that does not require strain attenuation or observation of possible adverse reactions after inoculation.
-
Thirty-three whole genomes of L. casei have been sequenced and annotated in the GenBank database.
-
Compared with traditional vaccines, recombinant L. casei vaccines are easier to administer and more cost-effective.
Published Data
Construction of PEDV recombinant Lactobacillus casei vaccine and its immune responses in mice
Abstract
The researchers have constructed a novel recombinant L. casei-OMP16-PEDVS strain expressing the PEDVS protein of PEDV and OMP16 protein of Brucella abortus strain. The results showed that serum IgG, neutralizing antibody, IL-4, IL-10, and INF-γ levels of L. casei-OMP16-PEDVS immunized mice were increased, and fecal IgG levels were increased, indicating that L. casei-OMP16-PEDVS vaccine candidate could induce higher levels of humoral immunity, cellular immunity, and mucosal immunity. Therefore, L. casei-OMP16-PEDVS can be used as a promising vaccine candidate to prevent PEDV infection.
Fig.2 The neutralizing antibody levels of candidate vaccines in the serum of immunized mice.2
Resources
Creative Biolabs has a team of experienced scientists who can help you achieve your preclinical research goals. We focus on probiotic and microbiological research, working side by side with our customers to accelerate project research progress. Please feel free to contact us for more details about our services, even if this is only an initial communication.
References
-
Song, Xin, et al. "CRISPR-Cas9D10A nickase-assisted genome editing in Lactobacillus casei." Applied and Environmental Microbiology 83.22 (2017): e01259-17.
-
Li, Xiaowen, et al. "The construction of recombinant Lactobacillus casei vaccine of PEDV and its immune responses in mice." BMC Veterinary Research 17 (2021): 1-10.
-
Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
